BetaEntity Annotation Prototype

Biomedical literature, made navigable

Follow the entities shaping the evidence.

Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.

Browse by entity family

An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.

View all families
29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed

Popular entities in these results

Choose an entity to see the articles in which it was identified.

Matching articles

29,499 articles · page 197 of 2459
90.5%
Buparlisibalpelisibbuparlisib with paclitaxelipatasertib with paclitaxelcapivasertib with paclitaxeltaselisib with fulvestrantcapivasertib plus fulvestrantpictilisib plus fulvestrantfulvestrantbuparlisib plus fulvestrant+1 more

…3-50.7); PFS=12.8 months (95% CI 6.6-18.8); ORR=not available]. Buparlisib plus fulvestrant presented the next best numerical efficacy [OS…

chronic lymphocytic leukaemiamultiple myelomachronic myeloid leukaemiahaematological malignanciesoral antineoplastic therapyoral antineoplastic agentsPubMedScopusEMBASEWeb of Science+3 more

…rence to oral antineoplastic therapy in patients diagnosed with chronic lymphocytic leukaemia, chronic myeloid leukaemia, or multiple myeloma.Material and Me…

Myopiacataractsmyopic macular degenerationretinal detachmentglaucomaHealth Insurance Fund0.05% atropineatropineLow-dose atropinePärnu Hospital Pharmacy+1 more

… of 5th graders and 22% of 10–14-year-olds affected in Estonia. Myopia raises the risk of serious eye diseases such as myopic macular …

TNFiaxSpAaxial spondyloarthritisSwiss Clinical Quality Management in Rheumatic Diseases registryAnkylosing Spondylitis Disease Activity Score

…).Conclusion We found no evidence for a better effectiveness of TNFi in patients with very early versus established axSpA.…